Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Equity (2021 - 2025)

Amylyx Pharmaceuticals has reported Return on Equity over the past 5 years, most recently at 0.0% for Q4 2025.

  • Quarterly results put Return on Equity at 0.0% for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was 0.0% (changed 0.0% YoY), and the annual figure for FY2025 was 0.0%, changed 0.0%.
  • Return on Equity for Q4 2025 was 0.0% at Amylyx Pharmaceuticals, down from 0.61% in the prior quarter.
  • Over the last five years, Return on Equity for AMLX hit a ceiling of 0.64% in Q4 2021 and a floor of 2.7% in Q1 2022.
  • Median Return on Equity over the past 5 years was 0.0% (2022), compared with a mean of 0.17%.
  • Biggest five-year swings in Return on Equity: soared 284bps in 2023 and later tumbled -162bps in 2024.
  • Amylyx Pharmaceuticals' Return on Equity stood at 0.64% in 2021, then crashed by -100bps to 0.0% in 2022, then surged by 9083bps to 0.12% in 2023, then crashed by -100bps to 0.0% in 2024, then plummeted by -739bps to 0.0% in 2025.
  • The last three reported values for Return on Equity were 0.0% (Q4 2025), 0.61% (Q3 2025), and 0.62% (Q2 2025) per Business Quant data.